Iscover

Clopidogrel, the active ingredient in Iscover, is a P2Y12 receptor antagonist presented as an oral formulation for oral use. It is indicated for the prevention of atherothrombotic events in patients who have experienced myocardial infarction, ischemic stroke, or have established peripheral arterial disease.

GNH USA supplies Iscover as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Iscover (clopidogrel) is used to reduce thrombotic risk in several cardiovascular conditions.

Recent myocardial infarction: reduces the risk of subsequent atherothrombotic events. Ischemic stroke: lowers the chance of recurrent stroke. Peripheral arterial disease: helps prevent cardiovascular events. Acute coronary syndrome: provides secondary prevention of cardiovascular events.

Clopidogrel may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Bleeding gums - Bruising - Nausea - Diarrhea

Serious or Rare Side Effects: - Severe bleeding (intracranial or gastrointestinal hemorrhage) - Thrombocytopenia - Allergic reactions such as rash or angioedema

When prescribing Iscover, clinicians should consider several precautionary measures to ensure patient safety.

Assess bleeding risk: evaluate patient history of hemorrhage before initiation. Monitor platelet function: consider laboratory testing in high‑risk individuals. Avoid in active pathological bleeding: discontinue the drug if significant bleeding occurs. Caution in hepatic impairment: adjust therapy as needed in patients with liver dysfunction. Review concomitant medications: check for drugs that increase bleeding risk. Store at ambient temperature: keep in the original container, protect from moisture.

Clopidogrel can interact with other medicines, altering its antiplatelet effect or increasing bleeding risk.

Major Interactions (Avoid): - Concurrent use with oral anticoagulants (e.g., warfarin, DOACs): heightened risk of severe bleeding. - Combination with NSAIDs or aspirin: increased hemorrhagic complications.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., omeprazole, fluoxetine): may reduce clopidogrel activation and antiplatelet efficacy. - CYP2C19 inducers (e.g., rifampin, carbamazepine): may lower drug effectiveness. - Selective serotonin reuptake inhibitors (SSRIs): can modestly increase bleeding tendency.